Back to Search
Start Over
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
- Source :
- Vaccines, Vol 9, Iss 214, p 214 (2021), Vaccines, Volume 9, Issue 3
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in clinical development and 173 are in the pre-clinical phase. Five types of vaccines are currently approved for emergency use in many countries (Inactivated, Sinopharm<br />Viral-vector, Astrazeneca, and Gamaleya Research Institute<br />mRNA, Moderna, and BioNTech/Pfizer). The main challenge in this pandemic was the availability to produce an effective vaccine to be distributed to the world’s population in a short time. Herein, we developed a whole virus NRC-VACC-01 inactivated candidate SARS-CoV-2 vaccine and tested its safety and immunogenicity in laboratory animals. In the preclinical studies, we used four experimental animals (mice, rats, guinea pigs, and hamsters). Antibodies were detected as of week three post vaccination and continued up to week ten in the four experimental models. Safety evaluation of NRC-VACC-01 inactivated candidate vaccine in rats revealed that the vaccine was highly tolerable. By studying the effect of booster dose in the immunological profile of vaccinated mice, we observed an increase in neutralizing antibody titers after the booster shot, thus a booster dose was highly recommended after week three or four. Challenge infection of hamsters showed that the vaccinated group had lower morbidity and shedding than the control group. A phase I clinical trial will be performed to assess safety in human subjects.
- Subjects :
- 0301 basic medicine
pre-clinical study
efficacy
Immunology
Population
lcsh:Medicine
Booster dose
immunogenicity
Article
Virus
03 medical and health sciences
0302 clinical medicine
Drug Discovery
Pandemic
Medicine
vaccine safety
Pharmacology (medical)
030212 general & internal medicine
education
Neutralizing antibody
Pharmacology
education.field_of_study
biology
SARS-CoV-2
business.industry
Immunogenicity
lcsh:R
Virology
Titer
030104 developmental biology
Infectious Diseases
biology.protein
Antibody
business
Subjects
Details
- ISSN :
- 2076393X
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Vaccines
- Accession number :
- edsair.doi.dedup.....a73ab93c09f221c745527a9041070528